AI TechBio company Caris Life Sciences (NASDAQ: CAI) declared on Wednesday that it has launched Caris Detect, a multi-cancer early detection blood test designed to identify cancer signals at earlier and more treatable stages using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and artificial intelligence.

The company said the test analyses DNA, RNA and broader molecular signals to provide a more comprehensive approach than existing screening methods, supported by its database of more than one million cases and over 50 billion molecular markers.

Caris said the launch is backed by data from the Caris Detect ACHIEVE 1 study, which demonstrated performance across multiple cancer types, and forms part of its broader strategy to advance early cancer detection and precision medicine.